anti-MAGE-A4 TCR T-cell therapy (bluebird bio/MediGene)

N/A

Report date: 2025/03/14 18:13:46

Base Information

Drug Nameanti-MAGE-A4 TCR T-cell therapy (bluebird bio/MediGene)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHuman leukocyte antigen modulatorsMelanoma-associated antigen 4 modulators
TargetsMelanoma-associated antigen 4Human leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedigene AgGenetix Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A